МЕРК ШАРП И ДОУМ КОРП. (US);МСД ИТАЛИЯ С.Р.Л. (IT)
发明人:
КЭРРОЛЛ Стивен С. (US),МАККОЛИ Джон А. (US),ОЛСЕН Дэвид Б. (US),СУММА Винченцо (IT),РОУЛИ Майкл (IT),ШТАЛЬХАТ Марк В. (US),ХАЗУДА Дария (US)
申请号：
RU2014122154/15
公开号：
RU2014122154A
申请日:
2012.10.26
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A pharmaceutical composition comprising: (i) a pharmaceutically acceptable carrier； (ii) a compound selected from table 1: or a pharmaceutically acceptable salt thereof； and (iii) one or more of the primary complementary drugs, or pharmaceutically acceptable salts thereof, wherein one or more of the primary complementary drugs is selected from the group consisting of HCV protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors and HCV NS5A inhibitors moreover, one or more of the primary additional medicines do not include the compound from table 1, and the amounts of the compounds from table 1 and one or more of the primary additional medicines in total These are effective in treating HCV infection in a patient, so if one or more of the primary complementary drugs includes an NS5A HCV inhibitor, then the NS5A HCV inhibitor is not one of the following compounds: or their pharmaceutically acceptable salts. 2. The pharmaceutical composition of claim 1, wherein one or more of the primary complementary drugs is selected from an HCV protease inhibitor and an HCV polymerase inhibitor. A pharmaceutical composition according to claim 1, characterized in that one or more of the primary complementary drugs includes an HCV polymerase inhibitor. The pharmaceutical composition according to claim 1, characterized in that one or more of the primary complementary drugs include an NS5A HCV.5 inhibitor. The pharmaceutical composition of claim 1, further comprising one or more of the secondary complementary drugs. Pharmaceutical composition p1. Фармацевтическая композиция, содержащая: (i) фармацевтически приемлемый носитель； (ii) соединение, выбранное из таблицы 1:или его фармацевтически приемлемую соль； и (iii) одно или более из первичных дополнительных лекарственных средств, или их фармацевтически приемлемые соли, при этом одно или более из первичных дополнительных лекарственных средств выбирают из группы, состоящей из ингибиторов протеазы HCV, ингибиторов полимеразы HC
